Hemostatic Disorders
Welcome,         Profile    Billing    Logout  
 199 Companies   329 Products   329 Products   164 Mechanisms of Action   13 Trials   3299 News 


«12...4567891011121314...6768»
  • ||||||||||  Jivi (damoctocog alfa pegol) / Bayer
    Trial primary completion date, Interview:  Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A (clinicaltrials.gov) -  Mar 15, 2017   
    P=N/A,  N=30, Not yet recruiting, 
    Recruiting --> Completed | Trial primary completion date: Jan 2017 --> Sep 2016 Trial primary completion date: Mar 2017 --> May 2017
  • ||||||||||  lenalidomide / Generic mfg.
    Biomarker, Trial completion:  Lenalidomide Maintenance Therapy for Multiple Myeloma (clinicaltrials.gov) -  Mar 14, 2017   
    P2,  N=11, Completed, 
    Recruiting --> Active, not recruiting Active, not recruiting --> Completed
  • ||||||||||  melphalan / Generic mfg., fludarabine IV / Generic mfg.
    Enrollment closed, Trial initiation date, Trial primary completion date:  Reduced Intensity Double Umbilical Cord Blood Transplantation (clinicaltrials.gov) -  Mar 3, 2017   
    P2,  N=33, Active, not recruiting, 
    N=30 --> 13 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2016 --> Dec 2016; Insufficient Accrual Recruiting --> Active, not recruiting | Initiation date: Sep 2011 --> Dec 2011 | Trial primary completion date: Aug 2016 --> Feb 2018
  • ||||||||||  Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
    Trial completion, Enrollment change, Trial primary completion date, Monotherapy:  XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease (clinicaltrials.gov) -  Feb 28, 2017   
    P1,  N=4, Completed, 
    Active, not recruiting --> Recruiting Active, not recruiting --> Completed | N=22 --> 4 | Trial primary completion date: Jun 2016 --> Aug 2014
  • ||||||||||  lenalidomide / Generic mfg.
    Trial primary completion date:  IFM2005-02: Maintenance Therapy Using Lenalidomide in Myeloma (clinicaltrials.gov) -  Feb 23, 2017   
    P3,  N=614, Active, not recruiting, 
    N=70 --> 100 Trial primary completion date: Sep 2016 --> Sep 2017
  • ||||||||||  Phase classification, Enrollment change, Trial initiation date, Trial primary completion date:  The Effect of the Nutraceutical "Hemofix" on the Coagulation System (clinicaltrials.gov) -  Feb 23, 2017   
    P=N/A,  N=0, Withdrawn, 
    Trial primary completion date: Sep 2016 --> Sep 2017 Phase classification: P1 --> P=N/A | N=40 --> 0 | Initiation date: Sep 2012 --> Sep 2016 | Trial primary completion date: Feb 2013 --> Jan 2020
  • ||||||||||  Xyntha (moroctocog alfa) / Pfizer
    Trial completion, Phase classification, Enrollment change:  Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO (clinicaltrials.gov) -  Feb 23, 2017   
    P=N/A,  N=87, Completed, 
    Phase classification: P1 --> P=N/A | N=40 --> 0 | Initiation date: Sep 2012 --> Sep 2016 | Trial primary completion date: Feb 2013 --> Jan 2020 Active, not recruiting --> Completed | Phase classification: P4 --> PN/A | N=120 --> 87
  • ||||||||||  Kogenate FS (octocog alfa sucrose formulation) / CSL Behring, Bayer
    Trial initiation date, Trial primary completion date, Patient reported outcomes:  ECHO: Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment (clinicaltrials.gov) -  Feb 23, 2017   
    P=N/A,  N=2000, Recruiting, 
    Active, not recruiting --> Completed | Phase classification: P4 --> PN/A | N=120 --> 87 Initiation date: Dec 2015 --> Dec 2016 | Trial primary completion date: Jun 2020 --> Dec 2020
  • ||||||||||  Onmel (itraconazole) / Merz Pharma
    Trial completion:  ATRA, Celecoxib, and Itraconazole as Maintenance (clinicaltrials.gov) -  Feb 23, 2017   
    P1,  N=1, Completed, 
    Initiation date: Dec 2015 --> Dec 2016 | Trial primary completion date: Jun 2020 --> Dec 2020 Active, not recruiting --> Completed
  • ||||||||||  bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
    Trial primary completion date:  RVD Lite: Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) (clinicaltrials.gov) -  Feb 23, 2017   
    P2,  N=53, Active, not recruiting, 
    Trial primary completion date: Oct 2014 --> Jan 2017 Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Enrollment change, Trial termination, Trial primary completion date, Combination therapy:  Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma (clinicaltrials.gov) -  Feb 14, 2017   
    P1,  N=9, Terminated, 
    N=18 --> 9 | Recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Jul 2016; The company providing one of the study drugs withdrew its support due to low enrollment. Therefore, we had to close the study due to lack of funding.
  • ||||||||||  Trial primary completion date:  Control of Major Bleeding After Trauma Study (clinicaltrials.gov) -  Feb 12, 2017   
    P2,  N=150, Recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: Apr 2017 --> Apr 2018
  • ||||||||||  Istodax (romidepsin) / Astellas, BMS
    Clinical:  Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma (clinicaltrials.gov) -  Feb 11, 2017   
    P1/2,  N=4, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | N=48 --> 4 | Trial primary completion date: Nov 2018 --> Oct 2016
  • ||||||||||  Trial primary completion date, Surgery:  INWOUND: Wound Healing Abnormalities in Major Abdominal Surgery (clinicaltrials.gov) -  Feb 8, 2017   
    P=N/A,  N=260, Recruiting, 
    Recruiting --> Completed | N=48 --> 4 | Trial primary completion date: Nov 2018 --> Oct 2016 Trial primary completion date: Oct 2016 --> Apr 2017